T1	PROC 44 74	Extensión de un ensayo clínico
T2	PROC 80 100	evaluar la seguridad
#1	AnnotatorNotes T2	C1705187; Safety Study; Research Activity
T3	CHEM 128 139	tobramicina
#2	AnnotatorNotes T3	C0040341; tobramycin; Antibiotic · Organic Chemical
T4	DISO 179 196	Fibrosis Quística
#3	AnnotatorNotes T4	C0010674; Cystic Fibrosis; Disease or Syndrome
T5	PROC 218 237;266 297	Extensión al ensayo fase IV, multicéntrico, abierto
T7	PROC 323 343	evaluar la seguridad
#4	AnnotatorNotes T7	C1705187; Safety Study; Research Activity
T8	CHEM 371 382	tobramicina
#5	AnnotatorNotes T8	C0040341; tobramycin; Antibiotic · Organic Chemical
T9	DISO 422 439	Fibrosis Quística
#6	AnnotatorNotes T9	C0010674; Cystic Fibrosis; Disease or Syndrome
T10	DISO 462 481	Infección bateriana
T11	DISO 499 516	fibrosis quística
#7	AnnotatorNotes T11	C0010674; Cystic Fibrosis; Disease or Syndrome
T12	ANAT 552 560	pulmonar
#8	AnnotatorNotes T12	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T13	DISO 613 630	fibrosis quística
#9	AnnotatorNotes T13	C0010674; Cystic Fibrosis; Disease or Syndrome
T14	PROC 676 712	consentimiento informado por escrito
#10	AnnotatorNotes T14	C0811741; Obtain informed written consent; Health Care Activity
T15	PROC 774 787	procedimiento
#11	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T16	PROC 911 920	protocolo
#12	AnnotatorNotes T16	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T17	PROC 925 945	estudio de extensión
T18	CHEM 975 985	Creatinina
#13	AnnotatorNotes T18	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T19	ANAT 986 992	sérica
#14	AnnotatorNotes T19	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T20	PROC 1008 1011	BUN
#15	AnnotatorNotes T20	C0005845; Blood urea nitrogen measurement; Laboratory Procedure
T21	PROC 1033 1050	análisis de orina
#16	AnnotatorNotes T21	C0042014; Urinalysis; Laboratory Procedure
T22	ANAT 1045 1050	orina
#17	AnnotatorNotes T22	C0042036; Urine; Body Substance
T23	DISO 1073 1084	proteinuria
#18	AnnotatorNotes T23	C0033687; Proteinuria; Finding
T24	PROC 1135 1155	estudio de extensión
T25	CHEM 1180 1197	diuréticos de asa
#19	AnnotatorNotes T25	C0354100; Loop Diuretics; Pharmacologic Substance
T26	PROC 1241 1261	estudio de extensión
T27	DISO 542 595	Infección pulmonar crónica con Pseudomonas aeruginosa
T28	PROC 1483 1511	prueba de laboratorio de HCG
#20	AnnotatorNotes T28	C1880076; Choriogonadotropin Beta Measurement; Laboratory Procedure
T29	CHEM 1508 1511	HCG
#21	AnnotatorNotes T29	C1141639; human chorionic gonadotropin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T30	PROC 1682 1706	método de anticoncepción
T31	PROC 1783 1792	protocolo
#22	AnnotatorNotes T31	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T32	PROC 975 992	Creatinina sérica
#23	AnnotatorNotes T32	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
T33	PROC 1735 1765	administración del tratamiento
T34	Date 12 16	2012
T35	Date 101 114	a largo plazo
T37	LIVB 165 174	pacientes
#24	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Duration 254 264	48 semanas
T39	Date 344 357	a largo plazo
T41	LIVB 408 417	pacientes
#25	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	LIVB 485 494	pacientes
#26	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	Duration 561 568	crónica
#27	AnnotatorNotes T43	C0205191; chronic; Temporal Concept
T44	LIVB 573 595	Pseudomonas aeruginosa
#28	AnnotatorNotes T44	C0033809; Pseudomonas aeruginosa; Bacterium
T45	LIVB 599 608	pacientes
#29	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T50	Duration 1201 1211	los 7 días
T51	LIVB 1266 1311	Mujeres embarazadas o en período de lactancia
#30	AnnotatorNotes T51	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T52	PHYS 1322 1330	embarazo
#31	AnnotatorNotes T52	C0032961; Pregnancy; Organism Function
T53	LIVB 1363 1368	mujer
#32	AnnotatorNotes T53	C0043210; Woman; Population Group
T54	PHYS 1383 1393	concepción
#33	AnnotatorNotes T54	C0009637; Conception; Organism Function | C0015914; Fertilization; Organism Function
T55	PHYS 1424 1433	gestación
#34	AnnotatorNotes T55	C0032961; Pregnancy; Organism Function
T56	LIVB 1545 1567	Mujeres en edad fértil
#35	AnnotatorNotes T56	C4324275; Woman of childbearing potential; Population Group
T57	Age 1556 1567	edad fértil
T59	LIVB 1594 1601	mujeres
#36	AnnotatorNotes T59	C0043210; Woman; Population Group
T62	Route 145 155	inhalación
T63	Route 388 398	inhalación
T66	PHYS 1639 1650	embarazadas
#37	AnnotatorNotes T66	C0032961; Pregnancy; Organism Function
T67	Form 119 124	polvo
T36	Form 362 367	polvo
T40	PHYS 1274 1285	embarazadas
#38	AnnotatorNotes T40	C0032961; Pregnancy; Organism Function
T47	PHYS 1302 1311	lactancia
#39	AnnotatorNotes T47	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T48	Result_or_Value 1051 1058	anormal
T49	PROC 1157 1163	visita
#40	AnnotatorNotes T49	C1512346; Patient Visit; Health Care Activity
T58	Quantifier_or_Qualifier 1164 1166	15
T60	Quantifier_or_Qualifier 1538 1540	15
T61	PROC 1531 1537	Visita
#41	AnnotatorNotes T61	C1512346; Patient Visit; Health Care Activity
#42	AnnotatorNotes T35	C0443252; Long-term; Temporal Concept
#43	AnnotatorNotes T39	C0443252; Long-term; Temporal Concept
#44	AnnotatorNotes T67	C0032861; Powder dose form; Biomedical or Dental Material
#45	AnnotatorNotes T62	C0205535; Inhalation Route of Drug Administration; Functional Concept 
#46	AnnotatorNotes T63	C0205535; Inhalation Route of Drug Administration; Functional Concept 
#47	AnnotatorNotes T5	C0282462; Phase 4 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C1709323; Open Label Study; Research Activity (?)
#48	AnnotatorNotes T10	C0004623; Bacterial Infections; Disease or Syndrome
#49	AnnotatorNotes T30	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
R1	Overlap Arg1:T2 Arg2:T35	
R2	Has_Drug_Form Arg1:T3 Arg2:T67	
R3	Has_Route_or_Mode Arg1:T3 Arg2:T62	
R4	Experiences Arg1:T37 Arg2:T3	
R5	Experiences Arg1:T37 Arg2:T4	
R7	Has_Duration_or_Interval Arg1:T5 Arg2:T38	
R6	Overlap Arg1:T7 Arg2:T39	
R8	Has_Route_or_Mode Arg1:T8 Arg2:T63	
R9	Has_Drug_Form Arg1:T8 Arg2:T36	
#50	AnnotatorNotes T36	C0032861; Powder dose form; Biomedical or Dental Material
R10	Experiences Arg1:T41 Arg2:T8	
R11	Experiences Arg1:T41 Arg2:T9	
R12	Experiences Arg1:T42 Arg2:T10	
R13	Before Arg1:T11 Arg2:T10	
R14	Experiences Arg1:T42 Arg2:T11	
R15	Location_of Arg1:T12 Arg2:T27	
R16	Has_Duration_or_Interval Arg1:T27 Arg2:T43	
R17	Causes Arg1:T44 Arg2:T27	
R18	Experiences Arg1:T45 Arg2:T13	
R19	Experiences Arg1:T45 Arg2:T27	
R20	Before Arg1:T13 Arg2:T27	
R21	Before Arg1:T14 Arg2:T15	
R22	Location_of Arg1:T19 Arg2:T32	
T6	Result_or_Value 993 1006	2 mg/dl o más
T46	Result_or_Value 1012 1026	40 mg/dl o más
R23	Has_Result_or_Value Arg1:T20 Arg2:T46	
R24	Has_Result_or_Value Arg1:T32 Arg2:T6	
R25	Location_of Arg1:T22 Arg2:T21	
R26	Has_Result_or_Value Arg1:T21 Arg2:T48	
T64	Result_or_Value 1085 1098	2+ o superior
R27	Has_Result_or_Value Arg1:T23 Arg2:T64	
T65	CONC 1119 1128	inclusión
#51	AnnotatorNotes T65	C1512693; Inclusion; Qualitative Concept
R28	Overlap Arg1:T32 Arg2:T65	
R29	Overlap Arg1:T20 Arg2:T65	
R30	Overlap Arg1:T21 Arg2:T65	
R31	Overlap Arg1:T23 Arg2:T65	
R33	Overlap Arg1:T65 Arg2:T49	
R34	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T58	
R35	Has_Duration_or_Interval Arg1:T25 Arg2:T50	
T68	CONC 1225 1234	inclusión
#52	AnnotatorNotes T68	C1512693; Inclusion; Qualitative Concept
R36	Before Arg1:T25 Arg2:T68	
R38	Experiences Arg1:T51 Arg2:T40	
R39	Experiences Arg1:T51 Arg2:T47	
R40	Experiences Arg1:T53 Arg2:T52	
R41	Experiences Arg1:T53 Arg2:T54	
R42	After Arg1:T52 Arg2:T54	
R43	Experiences Arg1:T53 Arg2:T55	
R44	Before Arg1:T54 Arg2:T55	
T69	Result_or_Value 1458 1476	resultado positivo
#53	AnnotatorNotes T69	C1446409; Positive; Finding
T70	Result_or_Value 1513 1523	> 5 mIU/mL
R45	Has_Quantifier_or_Qualifier Arg1:T61 Arg2:T60	
R46	Overlap Arg1:T28 Arg2:T61	
R47	Has_Result_or_Value Arg1:T28 Arg2:T69	
R48	Has_Result_or_Value Arg1:T28 Arg2:T70	
R49	Overlap Arg1:T52 Arg2:T61	
R50	Overlap Arg1:T55 Arg2:T61	
R51	Has_Age Arg1:T56 Arg2:T57	
R52	Experiences Arg1:T59 Arg2:T66	
R53	Experiences Arg1:T59 Arg2:T30	
R54	Experiences Arg1:T56 Arg2:T30	
R55	Overlap Arg1:T30 Arg2:T33	
T71	Observation 825 846	finalizado el estudio
#54	AnnotatorNotes T71	C2732579; Completion of clinical trial; Finding
T72	Observation 878 906	cumplir todos los requisitos
#55	AnnotatorNotes T72	C1302261; Patienteligible for clinical trial; Finding (?)
R56	Experiences Arg1:T51 Arg2:T61	
R57	Experiences Arg1:T53 Arg2:T61	
R60	Before Arg1:T71 Arg2:T16	
R61	Before Arg1:T71 Arg2:T17	
T73	Quantifier_or_Qualifier 1707 1723	altamente eficaz
R62	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T73	
T74	Observation 716 728	asentimiento
#56	AnnotatorNotes T74	C1302239; Patient consented to clinical trial; Finding (?)
R63	Before Arg1:T74 Arg2:T15	
R58	Overlap Arg1:T47 Arg2:T61	
R59	Overlap Arg1:T40 Arg2:T61	
#57	AnnotatorNotes T48	C0459424; Abnormal result; Finding
#58	AnnotatorNotes T33	C3469597; Administration of medication; Therapeutic or Preventive Procedure
R32	Overlap Arg1:T32 Arg2:T49	
R37	Overlap Arg1:T20 Arg2:T49	
R64	Overlap Arg1:T21 Arg2:T49	
R65	Overlap Arg1:T23 Arg2:T49	
R66	Overlap Arg1:T48 Arg2:T49	
R67	Experiences Arg1:T53 Arg2:T40	
A1	Experiencer T37 Patient
A2	Experiencer T41 Patient
A3	Experiencer T42 Patient
A4	Experiencer T45 Patient
A5	Experiencer T51 Patient
A6	Experiencer T53 Patient
A7	Experiencer T56 Patient
A8	Experiencer T59 Patient
